Acceptability of Zinc-fortified Lipid-based Nutrient Supplements

Assessment of the Acceptability of Zinc-fortified Lipid Based Nutrient (LNS) Prepared for Young Burkinabe Children

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00944814

Enrollment

Registered

2009-07-23

Start date

2009-07-31

Completion date

2009-08-31

Last updated

2017-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition

Keywords

Lipid-based nutrient supplement, Prevention of malnutrition, Prevention of micronutrient deficiencies, Zinc

Brief summary

The purpose of the study is to assess the acceptability of the two lipid-based nutrient supplement (LNS) formulations containing no zinc and a high amount of zinc (10 mg zinc / 20 g dose of LNS). The hypothesis is that both products will be equally accepted by children and mothers.

Detailed description

We plan to conduct a series of acceptability studies to: 1) assess the amounts of zinc-free and high-zinc LNS consumed by children during direct observation, 2) compare their mothers' sensory assessments of the respective products, and 3) review maternal reports of their child feeding experiences during more prolonged home feeding trials.

Interventions

DIETARY_SUPPLEMENTLNS with zinc

Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose

DIETARY_SUPPLEMENTLNS without zinc

LNS containing no zinc

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

9 Months to 15 Months

Healthy volunteers

Yes

Inclusion criteria

* Currently breast-feeding and consuming complementary foods for at least 30 d

Exclusion criteria

* Height-for-age and weight-for height Z-scores \<-3 with respect to WHO growth standards * Edema * Diarrhea and other diseases that could interfere with food intake * Severe systemic illness * History of peanut allergy * History of anaphylaxis/serious allergic reaction Infants meeting these criteria and their mother's will be invited to participate

Design outcomes

Primary

Measure	Time frame
Amount of each type of LNS formulation consumed by young children	3 days
Preference and detection of differences between LNS formulations among mothers	3 days
Acceptability of feeding LNS to young children at home	2 weeks

Countries

Burkina Faso

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026